
Medlab is a leader and innovator in the probiotic industry, offering a unique, clinically effective range of disease-specific, patent-protected MultiBiotic and NGR MultiBiotic products.

Medlab Clinical is a medical research and development facility dedicated to researching and formulating novel bio-therapeutics, including nutraceuticals and pharmaceuticals, aimed at improving health outcomes in early to moderate-stage chronic diseases such as chronic kidney disease and pre-diabetes/obesity.
Understanding Chronic Diseases
Understanding the impact of chronic diseases is essential. According to the Australian Institute of Health and Welfare (AIHW), nearly 9 in 10 (89%) of deaths in 2020 were associated with 10 chronic diseases (source: AIHW).
Finding Solutions for Chronic Diseases
Medlab focuses on researching bacteria and developing biological medicines that support human health by addressing the root cause, often in the gut. The company creates innovative medicines, including those derived from bacterial metabolites and bioavailable cannabinoids, to manage pain associated with conditions such as cancer, HIV/AIDS, and chronic diseases.
Medlab employs nanotechnology to deliver medicines in nanoparticles that are more easily absorbed when administered directly into the mouth or nose. The company develops next-generation pharmaceutical solutions for better delivery and improved pharmacokinetics, such as statins, to enhance health outcomes and reduce side effects.
Research begins at the molecular level with genome sequencing and progresses through cell culture studies, animal studies (when appropriate), and human trials. Collaborative partnerships are formed when necessary to access larger patient populations and offer multi-centre perspectives on trial outcomes.
Are you a health practitioner who would like to access these products?
If you are a patient and would like to access these products, use our map to find your local Practitioner.








